May 23rd 2025
From breast cancer to head and neck tumors, the 2025 ASCO Annual Meeting may feature a wide range of practice-changing data across cancer care.
EC-18 Yields Positive Results for Chemoradiation-Induced Oral Mucositis in Head and Neck Cancer
October 21st 2021A phase 2 trial examining the use of small molecule immunomodulator EC-18 in patients with head and neck cancer experiencing chemoradiation-induced oral mucositis met its primary and secondary end points.
VERSATILE-002 Trial to Enroll Previously Treated HPV+ HNSCC Per Protocol Amendment
June 3rd 2021A new treatment arm of a phase 2 trial examining PDS0101 plus pembrolizumab in patients with HPV-related head and neck cancers will be opened to patients with immune checkpoint inhibitor–pretreated disease.
Tislelizumab Combination Met Primary End Point for First-Line Treatment of Nasopharyngeal Cancer
May 21st 2021BeiGene’s press release details the positive progression-free survival data observed with the combination of tislelizumab plus chemotherapy compared with placebo plus chemotherapy for patients with recurrent or metastatic nasopharyngeal cancer.
First-Line Treatment With TPEx Regimen Did Not Improve OS Compared With EXTREME For HNSCC
April 8th 2021Docetaxel in combination with cisplatin and cetuximab did not significantly improve overall survival compared with platinum chemotherapy plus fluorouracil and cetuximab but maintained a favorable safety profile.
Avelumab Plus Chemotherapy Fails in HNSCC Phase 3 Trial, Raises Future Research Questions
April 2nd 2021Despite the success of immune checkpoint blockade in the treatment of recurrent or metastatic head and neck squamous cell carcinoma, the use of the PD-L1 inhibitor avelumab failed to prolong progression-free survival for patients with locally advanced disease.
FDA Grants Breakthrough Therapy to Cabozantinib to Treat Patients with Differentiated Thyroid Cancer
March 17th 2021Exelixis recently announced that cabozantinib received a breakthrough therapy designation from the FDA based on data from the COSMIC-311 trial for the treatment of differentiated thyroid cancer.
Lower Radiotherapy Dose Shows Promise for Treating HPV-Related Oropharyngeal Cancer
March 3rd 2021Given the current study findings, investigators suggested intratherapy personalization of chemoradiotherapy may possibly facilitate marked de-escalation of radiotherapy in patients with HPV-related oropharyngeal cancers.
FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC
February 24th 2021The breakthrough therapy designation was based on preliminary activity reported in the phase 2 RUN-HN clinical trial, which evaluated tipifarnib in patients with recurrent or metastatic HRAS-mutant head and neck squamous cell carcinoma.